

Attorney Docket No.: BMS-0015
Inventors: Salvati et al.
Serial No.: 09/885,827
Filing Date: June 20, 2001
Page 4

This listing of the claims will replace all prior versions and listings of claims in the application:

Listing of the claims:

a
Claim 1 (currently amended): A method for inhibiting the growth of hormone-dependent tumor cells in a patient in need thereof, comprising administering to said patient a selective androgen receptor modulator in an amount effective therefor, wherein said selective androgen receptor modulator exhibits antagonist activity in inhibiting growth of said hormone-dependent tumor while exhibiting no activity or agonist activity against other, nontumor tissues containing the androgen receptor.

Claim 2 (original): The method of claim 1, wherein said tumor cells are prostate tumor cells and wherein, in addition to exhibiting antagonist activity in said tumor cells and no activity or agonist activity against other, nontumor tissues containing the androgen receptor, said selective androgen receptor modulator further exhibits agonist, antagonist or no activity in normal prostate tissue.

Claim 3 (original): The method of claim 1, wherein said selective androgen receptor modulator exhibits agonist activity against other, nontumor tissues containing the

Attorney Docket No.: BMS-0015
Inventors: Salvati et al.
Serial No.: 09/885,827
Filing Date: June 20, 2001
Page 5

androgen receptor.

Claim 4 (original): The method of claim 1, wherein said selective androgen receptor modulator exhibits no activity against other, nontumor tissues containing the androgen receptor.

Claim 5 (original): The method of claim 1, wherein said hormone-dependent tumor is prostate cancer.

Claim 6 (original): The method of claim 1, wherein said other, nontumor tissue containing the androgen receptor comprises one or more of the following tissues: seminal vesicles, male and female genitalia, skin, testis, ovary, cartilage, sebaceous glands, hair follicles, sweat glands, muscle, gastrointestinal vesicular cells, thyroid follicular cells, adrenal cortex, liver, pineal, bone, stromal cells, kidney tubules, urinary bladder and/or brain cortical and subcortical regions.

Claim 7 (original): The method of claim 6, wherein said other, nontumor tissue containing the androgen receptor comprises one or more of the following tissues: cardiac muscle, skeletal muscle and/or smooth muscle.

Claim 8 (canceled)

Claim 9 (currently amended): A method for the treatment

Attorney Docket No.: BMS-0015
Inventors: Salvati et al.
Serial No.: 09/885,827
Filing Date: June 20, 2001
Page 6

of a condition remediable by administration of the a selective androgen receptor modulator of claim 8 which exhibits antagonist activity in a hormone-dependent tumor while exhibiting no activity or agonist activity against other, nontumor tissues containing the androgen receptor, comprising administering to a patient said selective androgen receptor modulator in an amount effective therefor, wherein said condition is selected from the following: hirsutism, acne, seborrhea, Alzheimer's disease, androgenic alopecia, hypogonadism, hyperpilosity, benign prostate hypertrophy, adenomas or neoplasias of the prostate, treatment of benign or malignant tumor cells containing the androgen receptor, pancreatic cancers, modulation of vascular endothelial growth factor (VEGF) expression for use as antiangiogenic agents, osteoporosis, suppressing spermatogenesis, libido, cachexia, endometriosis, polycystic ovary syndrome, anorexia, androgen dependent age-related diseases and conditions, male menopause, male hormone replacement, male and female sexual dysfunction, and inhibition of muscular atrophy in ambulatory patients.

Claim 10-24 (canceled)